Key result
Simvastatin matches ezetimibe/simvastatin for endothelial improvements, indicating lipid lowering drives the benefit.
Why the study?
The importance of the pleiotropic effects of statins on endothelial function and inflammatory markers in patients with dysglycaemia and CAD was not established.
Does simvastatin 80 mg daily improve endothelial function and inflammatory markers compared to ezetimibe 10 mg plus simvastatin 10 mg daily in patients with dysglycaemia and CAD?
RCT (n=39)
Does simvastatin 80 mg daily improve endothelial function and inflammatory markers compared to ezetimibe 10 mg plus simvastatin 10 mg daily in patients with dysglycaemia and CAD?
Lipid lowering itself, rather than statin pleiotropic effects, appears to be the primary driver of improvements in endothelial function and inflammatory markers in patients with dysglycaemia and CAD.
Answers are grounded in this paper and cite their sources.
Reinforces LDL reduction as primary driver of endothelial benefits in dysglycaemic CAD; challenges primacy of statin pleiotropic effects.
AIMS: The importance of pleiotropic effects of statins on endothelial function and inflammatory markers was investigated in patients with dysglycaemia and coronary artery disease (CAD). METHODS AND RESULTS: Thirty-nine patients were randomized to simvastatin 80 mg daily (S80; n = 20) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10; n = 19) for 6 weeks, aiming at similar cholesterol reduction. Endothelial function, evaluated by brachial artery flow-mediated vasodilatation (FMD) and the effect of endothelin receptor blockade, serum lipids, and inflammatory markers were evaluated at baseline and follow-up. At follow-up, low-density lipoprotein cholesterol decreased from 3.1 (2.8-3.4) (median and quartiles) to 1.5 mmol/L (1.4-1.7) and from 3.0 (2.5-3.4) to 1.3 mmol/L (1.1-1.8), in the S80 and E10/S10 groups, respectively. In the entire study group, FMD increased from 4.3% (3.4-6.1) at baseline to 5.5% (3.4-6.6) at follow-up, while C-reactive protein decreased from 3.1 (1.7-7.6) to 2.3 mg/L (0.9-6.5). The changes in FMD and C-reactive protein from baseline to follow-up were not significantly different between patients on S80 and E10/S10 groups. Endothelin blockade enhanced endothelium-dependent vasodilatation both at baseline and follow-up. CONCLUSION: Lipid lowering is more important than pleiotropic effects of statins for improvement in endothelial function and inflammatory markers in patients with dysglycaemia and CAD.
No takes yet. Share an insight, caveat, or question.
Settergren et al. (2008) conducted an RCT in Dysglycaemia and coronary artery disease (n=39). Simvastatin vs. Ezetimibe 10 mg and simvastatin 10 mg daily was evaluated on Changes in brachial artery flow-mediated vasodilatation (FMD) and C-reactive protein. Simvastatin and ezetimibe/simvastatin 10/ produced similar improvements in endothelial function and inflammatory markers, indicating lipid lowering is more important than pleiotropic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: